Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BCYC
- Price
- 5.23
- Stock movement down
- -0.17 (-3.07%)
- Company name
- Bicycle Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 268.12M
- Ent value
- -234.73M
- Price/Sales
- 9.46
- Price/Book
- 0.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 0.94%
- 1 year return (CAGR)
- -56.23%
- 3 year return (CAGR)
- -40.04%
- 5 year return (CAGR)
- -27.91%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCYC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.46 |
| Price to Book | 0.43 |
| EV to Sales | -8.28 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.93M |
| EPS (TTM) | -3.62 |
| FCF per share (TTM) | -3.49 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 28.34M |
| Gross profit (TTM) | -156.03M |
| Operating income (TTM) | -290.02M |
| Net income (TTM) | -250.66M |
| EPS (TTM) | -3.62 |
| EPS (1y forward) | -3.68 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -550.59% |
| Operating margin (TTM) | -1023.40% |
| Profit margin (TTM) | -884.51% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 648.33M |
| Net receivables | 67.26M |
| Total current assets | 738.82M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 36.30M |
| Total assets | 763.95M |
| Accounts payable | 12.65M |
| Short/Current long term debt | 5.74M |
| Total current liabilities | 69.28M |
| Total liabilities | 145.47M |
| Shareholder's equity | 618.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -240.06M |
| Capital expenditures (TTM) | 2.15M |
| Free cash flow (TTM) | -241.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -40.53% |
| Return on Assets | -32.81% |
| Return on Invested Capital | -40.53% |
| Cash Return on Invested Capital | -39.11% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.46 |
| Daily high | 5.50 |
| Daily low | 5.31 |
| Daily Volume | 282K |
| All-time high | 61.14 |
| 1y analyst estimate | 21.10 |
| Beta | 1.64 |
| EPS (TTM) | -3.62 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| BCYC | S&P500 | |
| Current price drop from All-time high | -91.45% | -1.82% |
| Highest price drop | -91.45% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -47.21% | -10.84% |
| Avg time to new high | 33 days | 12 days |
| Max time to new high | 1070 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
268.12M
Marketcap category
Small-cap
Description
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Employees
305
Investor relations
-
SEC filings
CEO
Kevin Lee
Country
USA
City
Cambridge
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page